Lower antioxidant capacity in the prefrontal cortex of individuals with schizophrenia
- 9 September 2017
- journal article
- research article
- Published by SAGE Publications in Australian & New Zealand Journal of Psychiatry
- Vol. 52 (7) , 690-698
Abstract
The glutathione (GSH) pathway is the main antioxidant system to protect against oxidative stress in the human brain. In this study, we tested whether molecular components of the GSH antioxidant system are changed in dorsolateral prefrontal cortex tissue from people with schizophrenia compared to controls. The levels of total glutathione and reduced GSH were determined by fluorometric assay via quantifying thiols in extracts from frontal cortex of 68 people. Immunoblotting was used to measure levels of enzymes responsible for maintaining GSH, the glutamyl-cysteine ligase (GCL) catalytic subunit (GCLC) and the GSH peroxidase (GPx)-like protein (n = 74). Quantitative reverse transcription polymerase chain reaction (RT-PCR) was used to measure GCLC messenger RNA (mRNA) expression. Both total glutathione (t(66) = 2.467, p = 0.016) and reduced GSH (t(66) = 3.001, p = 0.004) levels were significantly less in people with schizophrenia than in controls. However, there were no significant differences in either GCLC-like protein (t(72) = −1.077, p = 0.285) or GCLC mRNA expression (t(71) = −0.376, p = 0.708) between people with schizophrenia and control subjects. There was also no significant difference of GPx-like protein levels between schizophrenia and controls (t(72) = −0.060, p = 0.952). Moreover, no significant correlations of putative confounding factors with GSH changes were detected. These results suggest that people with schizophrenia have impaired GSH antioxidant capacity, alongside normal levels of key regulatory proteins.Keywords
Funding Information
- National Health and Medical Research Council (APP1117079)
This publication has 36 references indexed in Scilit:
- The Glutathione System: A New Drug Target in Neuroimmune DisordersMolecular Neurobiology, 2014
- Meta-Analysis of Oxidative Stress in SchizophreniaBiological Psychiatry, 2013
- Increased inflammatory markers identified in the dorsolateral prefrontal cortex of individuals with schizophreniaMolecular Psychiatry, 2012
- Decreased levels of glutathione, the major brain antioxidant, in post-mortem prefrontal cortex from patients with psychiatric disordersInternational Journal of Neuropsychopharmacology, 2010
- Decreased glutathione levels and altered antioxidant defense in an animal model of schizophrenia: Long-term effects of perinatal phencyclidine administrationNeuropharmacology, 2010
- Transcriptome analysis of male–female differences in prefrontal cortical developmentMolecular Psychiatry, 2009
- Environmental toxicity, redox signaling and lung inflammation: The role of glutathioneMolecular Aspects of Medicine, 2009
- Oxidative stress in brain aging, neurodegenerative and vascular diseases: An overviewJournal of Chromatography B, 2005
- Supplementation of vitamin C with atypical antipsychotics reduces oxidative stress and improves the outcome of schizophreniaPsychopharmacology, 2005
- Haloperidol and clozapine, but not olanzapine, induces oxidative stress in rat brainNeuroscience Letters, 2004